ResearcherCapital Medical UniversityNo recent work listed

Qiaoyun Chu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7344-0395; OpenAlex author ID A5058336100. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine. Co-author DOI 10.1007/s13167-022-00287-0 ↗
CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation. Co-author DOI 10.1002/cam4.3916 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Simeng Zhang · 1 shared paper, 2022 · strength 0.19
- Paper TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, prev… DOI 10.1007/s13167-022-00287-0 ↗
Ce Li · 1 shared paper, 2022 · strength 0.19
- Paper TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, prev… DOI 10.1007/s13167-022-00287-0 ↗
Guan Wang · 1 shared paper, 2022 · strength 0.19
- Paper TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, prev… DOI 10.1007/s13167-022-00287-0 ↗
Youxin Wang · 1 shared paper, 2021 · strength 0.17
- Paper CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation. DOI 10.1002/cam4.3916 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.